Endoscopy
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Optimal Management of Conventional Adenomas in 2026: Current and Evolving Recommendations and Ongoing Controversies.
Clinical takeawayNo clinical action yet: a guideline review synthesizing existing recommendations and controversies without new human evidence.
What it foundReview summarizes current guidelines and controversies in adenoma detection, resection, and surveillance, including ADR thresholds, CADe impact, and dysplasia significance.
ContextConfirms and refines current practice by integrating established guidelines with emerging evidence and debates (e.g., ADR thresholds, CADe role).
Refinessuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017
Decision at stakethe surveillance intervals and techniques for adenoma management
U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.
Thakkar B … Anderson JC · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗